α-Bisabolol / Chamomile oil / Fas Cancer Research Results

BSB, α-Bisabolol / Chamomile oil: Click to Expand ⟱
Features:

α-Bisabolol — α-Bisabolol is a naturally occurring monocyclic sesquiterpene alcohol best known as a major bioactive constituent of chamomile essential oil, especially German chamomile (Matricaria chamomilla / Matricaria recutita) and related chamomile preparations. It is a small lipophilic phytochemical classified as a plant-derived essential-oil terpene alcohol, with common abbreviations including α-BSB, BSB, and levomenol for the (-)-α-bisabolol enantiomer. In oncology research it is mainly a preclinical pro-apoptotic and anti-invasive compound with preferential mitochondrial stress effects in cancer models; in clinical deployment it remains a cosmetic/natural-health constituent rather than an approved anticancer drug.

-The main components in German chamomile are terpenoid; α-bisabolol and its oxide azulenes, such as chamazulene (1–15%); and apigenin. Roman chamomile, on the other hand, contains mainly angelic acid and tiglic acid esters. Apigenin is a main bioactive component and considered a quality marker of chamomile.

Primary mechanisms (ranked):

  1. Mitochondria-centered apoptosis through mitochondrial membrane depolarization, permeability transition pore involvement, oxygen-consumption disruption, and downstream caspase activation.
  2. Membrane/lipid-raft-mediated cellular uptake and organelle accumulation, contributing to preferential toxicity in malignant cells with altered membrane and mitochondrial physiology.
  3. Suppression of migration, invasion, and adhesion-associated signaling in selected cancer models, including pancreatic and lung cancer cell systems.
  4. PI3K/AKT and NF-κB pathway suppression in selected models, with context-dependent reduction of survival and inflammatory signaling.
  5. Radiosensitization or chemosensitization in limited preclinical settings, including XIAP/caspase-3-associated enhancement of radiation-induced apoptosis and reported interactions with standard cytotoxic stress models.
  6. ROS/redox modulation as a secondary, context-dependent axis: antioxidant/anti-inflammatory in normal inflammatory models, but pro-death mitochondrial stress may dominate in susceptible cancer cells.

Bioavailability / PK relevance: α-Bisabolol is highly lipophilic and poorly water soluble, so systemic translation depends strongly on formulation, route, dose, and vehicle. Essential-oil or neat-compound exposure does not imply predictable plasma exposure, and advanced delivery systems such as cyclodextrin complexes, nanoemulsions, or lipid carriers may be required for reproducible systemic or CNS delivery.

In-vitro vs systemic exposure relevance: Most anticancer findings use direct in-vitro exposure at micromolar to high-micromolar concentrations, often with solvent-assisted delivery. These concentrations may exceed achievable free systemic exposure after ordinary chamomile tea, dietary chamomile, or topical/cosmetic use. Chamomile oil composition is also chemotype-dependent, so α-bisabolol content can vary substantially.

Clinical evidence status: Cancer evidence is preclinical only. There are human trials of α-bisabolol-containing topical products for non-cancer indications, and chamomile has natural-health/traditional-use monographs for digestive, inflammatory gastrointestinal, and calmative uses, but there is no established human oncology indication, no approved anticancer label, and no cancer RCT evidence for α-bisabolol or chamomile oil.

Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondria / MPTP ↑ MPTP opening, ↓ mitochondrial membrane potential, ↓ oxygen consumption ↔ or lower sensitivity (model-dependent) R/G Intrinsic apoptosis Core anticancer mechanism; supported most strongly in glioma and other transformed-cell models.
2 Caspase apoptosis / XIAP ↑ caspase-3 activity, ↓ XIAP restraint (model-dependent) ↔ or protective inflammatory modulation (context-dependent) G Execution-phase apoptosis Important for radiation-enhanced apoptosis in endometrial cancer cells and general pro-apoptotic activity.
3 Lipid rafts / organelle entry ↑ lipid-raft-mediated uptake and intracellular delivery ↔ (model-dependent) P/R Preferential intracellular accumulation Likely upstream determinant of selective mitochondrial and lysosomal stress.
4 Cell migration / invasion ↓ motility, ↓ invasion, ↓ invasive phenotype ↔ G Anti-metastatic phenotype Reported in pancreatic cancer and lung cancer models; therapeutically interesting but still preclinical.
5 PI3K / AKT survival signaling ↓ PI3K/AKT signaling (model-dependent) ↔ or mixed G Reduced survival signaling Secondary/contextual mechanism; not yet a clean validated primary target axis.
6 NF-κB / inflammatory signaling ↓ NF-κB-associated survival or inflammatory signaling (model-dependent) ↓ inflammatory cytokine signaling G Anti-inflammatory and pro-apoptotic context shift May be protective in normal inflammatory tissue while reducing survival signaling in some cancer models.
7 ROS / redox stress ↑ mitochondrial stress or mixed ROS effects (context-dependent) ↓ oxidative/inflammatory stress (context-dependent) R/G Context-dependent redox modulation Not a simple pro-oxidant; antioxidant and anti-inflammatory effects are common outside cancer models.
8 NRF2 / antioxidant response ↔ or mixed (model-dependent) ↑ antioxidant defense reported in some injury models G Secondary cytoprotection Include as secondary only; not the central anticancer mechanism for α-bisabolol.
9 Radiosensitization ↑ radiation-induced apoptosis (requires external trigger) Unknown; possible normal-tissue protection in inflammatory injury models G Adjunct sensitization Promising but narrow evidence base; not clinically established.
10 Chemosensitization ↑ cytotoxic stress response (model-dependent) Potential tissue-protective effects in doxorubicin injury models G Adjunct interaction Direction may differ by tissue: anticancer sensitization versus normal-organ protection requires careful separation.
11 Clinical Translation Constraint Direct in-vitro exposure may not match systemic exposure Safety generally favorable but allergy and formulation constraints remain G Bioavailability and evidence limitation Poor aqueous solubility, variable chamomile-oil composition, limited PK data, and lack of oncology trials are the main constraints.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Alzheimer’s disease relevance: α-Bisabolol has meaningful preclinical AD relevance through amyloid-β toxicity reduction, mitochondrial protection, anti-inflammatory activity, oxidative-stress reduction, and possible cholinesterase-related effects. Evidence includes Aβ-induced cell and animal/C. elegans models, scopolamine-memory models for α-bisabolol derivatives, and chamomile essential-oil studies with α-bisabolol-rich composition. However, there is no established human AD clinical evidence for α-bisabolol, and brain exposure is likely formulation-dependent because the compound is lipophilic and poorly water soluble.
Fas, Fas Death receptor: Click to Expand ⟱
Source:
Type:
Fas (also known as CD95 or APO-1) and Fas ligand (FasL) are proteins that play a crucial role in the regulation of programmed cell death, also known as apoptosis.

The Fas/FasL system is involved in the elimination of damaged or unwanted cells, including cancer cells.
Fas agonists, which mimic the action of FasL, have been shown to induce apoptosis in cancer cells. FasL inhibitors, which block the interaction between Fas and FasL, have been shown to enhance the effectiveness of chemotherapy and immunotherapy

Fas is often expressed ,and may be associated with better responses to chemotherapy, but its role in promoting cell survival in certain contexts can complicate its prognostic implications.
Scientific Papers found: Click to Expand⟱
6542- BSB,    Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of α-Bisabolol
- Review, Var, NA - Review, Park, NA - Review, AD, NA
AntiCan↑, *neuroP↑, *cardioP↑, *AntiBio↑, *BioAv↑, *toxicity↓, *BioAv↑, *motorD↑, *SOD↑, *Catalase↑, *Keap1↑, *MDA↓, *GSH↑, *IL1β↓, *IL6↓, *TNF-α↓, *iNOS↓, *COX2↓, *lipid-P↓, *Cyt‑c↓, *ROS↓, *MMP↑, *antiOx↑, *AChE↓, *Apoptosis↓, *BAX↓, *Casp3↓, *Bcl-2↑, *BACE↓, *BChE↓, *eff↑, *Aβ↓, *ATP↑, RadioS↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Apoptosis↑, PARP↑, BAX↑, BID↑, NF-kB↑, Fas↑, EGFR↑, TIMP2↑, XIAP↓, COX2↓, Bak↓, Bcl-2↓, P53↑, HER2/EBBR2↓, FGF↓, CEA↓, Akt↓, TumCCA↑, *Imm↑, *CD4+↑, *CD8+↑, *BBB↑, *Pain↓, *cardioP↑, *TBARS↓, *SOD↑, *Catalase↑, *GSH↑, *AntiBio↑, *AntiFungal↑, *GastroP↑, *RenoP↑, *creat↓, *uricA↓, *Inflam↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL6↑, *MMP13↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Bak↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   BID↑, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

FGF↓, 1,  

Migration ⓘ

CEA↓, 1,   TIMP2↑, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   NF-kB↑, 1,  

Drug Metabolism & Resistance ⓘ

RadioS↑, 1,  

Clinical Biomarkers ⓘ

CEA↓, 1,   EGFR↑, 1,   HER2/EBBR2↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiBio↑, 2,  

Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 2,   GSH↑, 2,   Keap1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 1,   SOD↑, 2,   TBARS↓, 1,   uricA↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   MMP↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c↓, 1,   iNOS↓, 2,  

Migration ⓘ

MMP13↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GastroP↑, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX2↓, 2,   IL1β↓, 1,   IL6↓, 1,   IL6↑, 1,   Imm↑, 1,   Inflam↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   eff↑, 1,  

Clinical Biomarkers ⓘ

creat↓, 1,   IL6↓, 1,   IL6↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   motorD↑, 1,   neuroP↑, 1,   Pain↓, 1,   RenoP↑, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

AntiFungal↑, 1,   CD8+↑, 1,  
Total Targets: 47

Scientific Paper Hit Count for: Fas, Fas Death receptor
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:413  Target#:112  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page